Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 25Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer 1

Interventions

3-Iodobenzylguanidine 9Cyclophosphamide 6Amifampridine 6nilotinib 5fludarabine 5Magnetic Resonance Spectroscopy 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine phosphate 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × patritumab deruxtecan × Clear all
NCT06099639 2025-06-08

Medical Access Program for Patritumab Deruxtecan

Daiichi Sankyo

No longer available
Thoracic

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡